LAVA Medtech Acquisition Corp. (LVACU) Prices $100M IPO

LAVA Medtech Acquisition Corp. announced the pricing of its $100 million IPO and its shares are expected to begin trading on the Nasdaq under the symbol “LVACU” Wednesday, October 27.

The new SPAC intends to combine with an innovative, early commercial-stage company in the healthcare and healthcare-related industries with a focus on clinically-impactful and high growth opportunities in medical devices, diagnostics, and digital health. LAVA Medtech is led by CEO Anthony Natale, Chairman Richard Emmitt, President Gerry Brunk, EVP Daniel Hetu, and CFO Vasco Larcina.

Total SPAC deal count for 2021 year-to-date is now 491. This offering is expected to close on Friday, October 29.

RBC Capital Markets is serving as the sole book-running manager for the offering. Reed Smith LLP is serving as Issuer’s Counsel with Skadden, Arps, Slate, Meagher & Flom LLP serving as Underwriter’s Counsel. Citrin Cooperman & Company, LLP serves as auditor. Continental Stock Transfer & Trust Company is acting as trustee.